Amendment No. 2 to the Commercialization and Reference Laboratory AgreementCommercialization and Reference Laboratory Agreement • November 6th, 2024 • Personalis, Inc. • Services-medical laboratories
This Amendment No. 2 (“Amendment”) is made as of the date of the last signature below (“Amendment Date”) between Personalis, Inc. (“Personalis”) and Tempus AI, Inc. f/k/a Tempus Labs, Inc. (“Tempus”) and amends that certain Commercialization and Reference Laboratory Agreement with the effective date of November 25, 2023 (as previously amended, the “Agreement”). Tempus and Personalis are each a “Party” and together the “Parties.”
Amendment No. 1 to the Commercialization and Reference Laboratory AgreementCommercialization and Reference Laboratory Agreement • August 16th, 2024 • Personalis, Inc. • Services-medical laboratories
This Amendment No. 1 (“Amendment”) is made as of the date of the last signature below (“Amendment Date”) between Personalis, Inc. (“Personalis”) and Tempus AI, Inc. f/k/a Tempus Labs, Inc. (“Tempus”), and amends the Commercialization and Reference Laboratory Agreement with the effective date of November 25, 2023 (the “Agreement”). Tempus and Personalis are each a “Party” and together the “Parties.” The Parties wish to modify the terms of the Agreement as set forth herein. In consideration of the mutual promises herein, the Parties agree as follows:
Commercialization and Reference Laboratory AgreementCommercialization and Reference Laboratory Agreement • November 28th, 2023 • Personalis, Inc. • Services-medical laboratories • Delaware
This Commercialization and Reference Laboratory Agreement (“Agreement”) is entered into by and between Tempus Labs, Inc., with its principal place of business at 600 West Chicago Ave., Suite 510, Chicago, Illinois 60654 (“Tempus”), and Personalis, Inc., with its principal place of business at 6600 Dumbarton Circle, Fremont, CA 94555 (“Personalis”). Tempus and Personalis may each be referred to individually as a “Party” and collectively as the “Parties.”
